3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
36
Genitourinary
28
Gastrointestinal
27
Thoracic
17
Head & Neck
12
Tumor-Agnostic
11
Other hematologic neoplasm
11
Gynecologic
11
Plasma cell
9
Lymphoid
8
Dermatologic
4
Sarcoma
3
Other
3
Myeloid
3
Endocrine
3
CNS
3
Other solid neoplasm
2
Classical hematology
2
NET
1
Conditions
Neuroendocrine Tumors
1
Interventions
Everolimus
19
lutetium Lu 177 dotatate
8
Octreotide
8
lanreotide
7
pasireotide
6
Temozolomide
6
Sunitinib
6
pembrolizumab
5
gallium Ga 68 dotatate
5
Positron Emission Tomography Computed Tomography
5
surufatinib
4
Sorafenib
4
Data Collection
4
Carboplatin
4
3-Iodobenzylguanidine
4
Positron-Emission Tomography
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Capecitabine
3
90Y-octreotide, DOTA-Tyr(3)-
3
pentetreotide
2
pazopanib
2
lenvatinib
2
fosbretabulin
2
fluorodopa F 18
2
cabozantinib
2
avelumab
2
arginyllysine
2
Single Photon Emission Computed Tomography Computed Tomography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Standard of Care
×
NET
×
Clear all
NCT02472678
2024-05-06
WIN
University Medical Center Groningen
Phase NA
Completed
91 enrolled